Nowell Peter C
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6082, USA.
J Clin Invest. 2007 Aug;117(8):2033-5. doi: 10.1172/JCI31771.
Almost 50 years ago, David Hungerford and I noticed an abnormally small chromosome in cells from patients with chronic myelogenous leukemia (CML). This article is a personal perspective of the events leading to the discovery of this chromosome, which became known as the Philadelphia chromosome. As technology advanced over subsequent decades, the translocation resulting in the Philadelphia chromosome has been identified, its role in the development of CML has been confirmed, and a therapy directed against the abnormal protein it produces has shown promising results in the treatment of patients with CML.
大约50年前,我和大卫·亨格福德注意到慢性粒细胞白血病(CML)患者细胞中的一条异常小染色体。本文是对导致发现这条染色体(即后来所知的费城染色体)的事件的个人视角阐述。在随后的几十年里,随着技术的进步,导致费城染色体出现的易位已被确定,其在CML发展中的作用已得到证实,并且一种针对它所产生的异常蛋白质的疗法在治疗CML患者方面已显示出有前景的结果。